Olympia Pharmacy complaints: diagnose documented symptoms, not rumors.
Unlike many B2B compounding platforms, Olympia Pharmacy has publicly documented issues worth investigating directly. The FDA Form 483 issued May 29, 2024, cited 167 uninvestigated complaints within a three-month window (March to May 2024) — including complaints about specific lots of glutathione, sodium bicarbonate, and tirzepatide products. BBB complaints (no accreditation) describe cold-chain problems (medications arriving without proper cold storage), billing disputes, and in at least one case an allegation of unauthorized charges after providing payment information. Third-party summary sites rate Olympia Pharmaceuticals at 1.0 out of 5 on ComplaintsBoard based on 8 reviews as of June 2026. This page maps these documented issues to root causes and the direct questions that confirm whether they apply to your clinic.
These are not rumors — they are documented in public records. This page turns each one into a specific question to bring to your Olympia Pharmacy demo.
Proudly Partnered With
Documented issues, root causes, and what to confirm
Each row names a documented complaint theme or structural risk, rates how concerning it is for a clinic evaluating Olympia Pharmacy, and shows the root cause. All documented sources are cited below.
- Significant — verified
Complaint handling gaps
FDA Form 483 (May 2024) found that Olympia Pharmaceuticals failed to investigate 167 complaints received between March and May 2024, including complaints about specific product lots. Root cause: the compliance team was working retroactively rather than in real time. Ask what has changed in their complaint intake and investigation process since May 2024.
- Documented — verify
Cold-chain handling
BBB complaints include accounts of temperature-sensitive medications arriving without proper cold-chain storage. Root cause: shipping and cold-chain failures can stem from packaging, carrier selection, or fulfillment timing. Ask Olympia Pharmacy how cold-chain products are packaged, which carrier is used, and what recourse is available if your shipment arrives compromised.
- Documented — verify
Billing disputes
BBB complaints describe billing errors and, in at least one complaint, an allegation of unauthorized charges after providing payment information. Root cause: billing errors can reflect manual invoicing gaps. Ask for itemized invoices in writing and clarify the payment authorization flow during onboarding.
- Regulatory — verify directly
Aseptic processing observations
FDA Form 483 (July–August 2025) cited deficiencies in aseptic processing area cleaning, cleaning validation, and personnel gowning. Root cause: sterile compounding environment failures can affect product safety. Review the full 483 at fda.gov and ask Olympia Pharmacy what corrective actions were taken and their status.
- Product change — confirm SKUs
GLP-1 pivot
Olympia Pharmaceuticals pivoted from semaglutide and tirzepatide compounding to liraglutide following FDA shortage declaration endings. If your clinic previously ordered semaglutide or tirzepatide from Olympia, confirm which weight-management SKUs are currently available and at what terms.
- Structural — quote-only
Pricing visibility
Root cause: because pricing is negotiated rather than published, slow quoting and rate surprises are inherent to the model. This is not a complaint per se, but it amplifies frustration when combined with billing disputes.
Documented findings sourced from public FDA records, BBB complaint summaries, and third-party reviews, reviewed June 2026. Not all complaints are verified; investigate each directly.
Investigate the documented issues, or design them out with pass-through?
Olympia Pharmacy
You have verified each documented issue and are satisfied with current corrective actions.
- You have reviewed FDA Form 483 reports (May 2024, August 2025) at fda.gov and discussed corrective actions with Olympia Pharmacy directly.
- Your cold-chain requirements can be verified with Olympia's packaging and carrier process before you commit.
- Your billing workflow can accommodate a quote-driven model with itemized invoices requested up front.
Fizy Health
You want documented issues prevented by design, not managed after the fact.
- You want per-vial pricing visible so billing is predictable before checkout — no retroactive invoice surprises.
- You want validation before payment so fewer paid orders ever get rejected or disputed.
- You want support and tracking that keep order context intact so issues are caught and resolved faster.
What it looks like when the documented symptoms are designed out.
These are the outcomes a clinic gets when pricing is visible, orders are validated before payment, and support and tracking stay in context.
Fewer paid orders rejected by the pharmacy
Cart validation catches invalid SIGs, prescriber state mismatches, and stock gaps before you pay — not after rejection.
Quote patients with real per-vial cost before the consult
See resolved 503A landed cost on each catalog and cart line before checkout, with a disclosed facilitation fee at payment.
Support tied to the order, not scattered across phone lines
In-app support tickets with threaded replies stay linked to the order and patient, so issues keep their full context.
Per-line status when one checkout splits across compounders
Per-line fulfillment and carrier tracking across every routed partner keeps tracking intact when orders split.
What clinics ask about Olympia Pharmacy issues.
- Definition
Are there documented Olympia Pharmacy complaints?
Yes — unlike many B2B platforms, Olympia Pharmacy has documented issues in public records. FDA Form 483 (May 2024) cited 167 uninvestigated complaints in a 3-month window. BBB complaints (no accreditation) describe cold-chain failures, billing errors, and alleged unauthorized charges. ComplaintsBoard rates Olympia Pharmaceuticals at 1.0/5 based on 8 reviews (June 2026). Review each source directly and ask Olympia Pharmacy what has changed.
- FDA
What did the FDA Form 483 find at Olympia Pharmacy?
The May 2024 Form 483 found that Olympia Pharmaceuticals failed to investigate 167 complaints received between March and May 2024, including complaints about specific lots of glutathione, sodium bicarbonate, and tirzepatide. The August 2025 Form 483 cited aseptic processing deficiencies including cleaning validation gaps and personnel gowning issues. Both are public records at fda.gov.
- Cold chain
What are the BBB cold-chain complaints about?
BBB complaint summaries describe temperature-sensitive medications arriving without proper cold-chain storage. If your clinic orders cold-stored peptides, NAD+, or injectables, ask Olympia Pharmacy specifically how those products are packaged, which carrier handles cold-chain shipments, and what recourse you have if a shipment arrives outside temperature range.
- GLP-1
What happened to Olympia Pharmacy's semaglutide and tirzepatide compounding?
Olympia Pharmaceuticals pivoted from semaglutide and tirzepatide to liraglutide following FDA shortage declaration endings. If your clinic previously used or is evaluating Olympia for GLP-1 weight-management compounding, confirm specifically which GLP-1 SKUs are currently available and under what regulatory framework.
- Comparison
How does Fizy Health prevent these issues?
Fizy Health shows pass-through pricing before checkout (no billing surprises), validates SIGs and licensure before payment (fewer rejected or disputed orders), and keeps support tickets linked to orders — preventing the documented symptoms rather than managing them after the fact.
- Decision
How do I confirm whether these issues apply to my clinic?
Ask Olympia Pharmacy directly in writing: What changed in your complaint handling process after May 2024? How do you handle cold-chain failures? What is your billing dispute resolution path? Then run a test order, request itemized invoicing, and verify the cold-chain process before committing.
Sources reviewed June 2026
- Olympia Pharmaceuticals FDA Form 483, May 29, 2024 — complaint handling observations including 167 uninvestigated complaints; public record at fda.gov.
- Olympia Pharmaceuticals FDA Form 483, July–August 2025 — aseptic processing observations; public record at fda.gov.
- Olympia Pharmaceuticals FDA Warning Letter, February 2014 — public record at fda.gov.
- glp-1.com review of Olympia Pharmaceuticals — BBB complaint themes and ComplaintsBoard rating summary (glp-1.com/providers/olympia-pharmaceuticals), reviewed June 2026.
- Olympia Pharmacy public website (olympiapharmacy.com), reviewed June 2026.
- Fizy Health platform capabilities reflect the live product.
Prevent the documented issues — don't just manage them.
Fizy Health shows pass-through pricing before you quote, validates orders before you pay, and keeps support in the app. Free to start.